Figure 1.
(A) Kaplan–Meier estimate of progression-free survival (PFS). (B) Kaplan–Meier estimate of PFS according to initial starting dose of regorafenib.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.